tradingkey.logo
tradingkey.logo
Search

Alar Breaks Key Barriers In Ketamine Therapy With Positive Phase 1 Results For Long-Acting Injectable Ala-3000 For Treatment-Resistant Depression

ReutersApr 6, 2026 12:20 PM

- Alar Pharmaceuticals Inc 6785.TWO:

  • ALAR BREAKS KEY BARRIERS IN KETAMINE THERAPY WITH POSITIVE PHASE 1 RESULTS FOR LONG-ACTING INJECTABLE ALA-3000 FOR TREATMENT-RESISTANT DEPRESSION

  • ALAR PHARMACEUTICALS INC - ALA-3000 MEETS PRIMARY ENDPOINT WITH FAVORABLE SAFETY AND TOLERABILITY PROFILE

  • ALAR PHARMACEUTICALS INC - NO CLINICALLY MEANINGFUL SAFETY CONCERNS IDENTIFIED FOR ALA-3000

  • ALAR PHARMACEUTICALS INC - NO DISSOCIATION, SEDATION, OR PSYCHOSIS-LIKE SYMPTOMS OBSERVED WITH ALA-3000

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI